Aegis lifts target on Ampio Pharmaceuticals

Aegis is out with some upbeat commentary on Ampio Pharmaceuticals (AMPE -1.7%) on the heels of the company's announcement that a subsidiary has struck research agreements with Western Galilee Medical Center and the University of Thessaly where researchers will "utilize Luoxis' proprietary RedoxSYS ORP diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion." (PR)

Additionally, analyst Selvaraju thinks "the company should be able to file for approval [for Ampion] with positive data from a single Phase 3 confirmatory trial."

Price target hiked to $15 from $14.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs